Checkpoint Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Checkpoint Therapeutics is holding a special meeting on May 28, 2025, for stockholders to vote on the proposed merger with Sun Pharmaceutical Industries, Inc.
Checkpoint Therapeutics and Sun Pharmaceutical Industries amend their merger agreement, modifying the definition of 'Company Required Vote' to include both a majority of unaffiliated stockholders and a majority of outstanding common stock.
Checkpoint Therapeutics announces a definitive agreement to be acquired by Sun Pharmaceutical Industries, Inc., pending stockholder approval and regulatory clearances.
DEFA14A: Sun Pharma to Acquire Checkpoint Therapeutics for Up to $416 Million, Bolstering Onco-Derm Franchise
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share plus a contingent value right of up to $0.70 per share, potentially reaching a total transaction value of $416 million.
Checkpoint Therapeutics is holding its annual meeting on May 13, 2024, seeking stockholder approval on several key proposals, including increasing authorized shares and amending the 2015 Incentive Plan.
DEF 14A: Checkpoint Therapeutics Seeks Stockholder Approval for Share Increase and Incentive Plan Amendment
Checkpoint Therapeutics is asking stockholders to approve an increase in authorized shares and an amendment to its incentive plan at the upcoming annual meeting.